Cetuximab for the Treatment of Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR. METHODS: From December 2003 to August 2005, 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine, irinotecan, and oxaliplatin or had contraindications to treatment with these drugs underwent randomization to an initial dose of 400 mg of cetuximab per square meter of body-surface area followed by a weekly infusion of 250 mg per square meter plus best supportive care (287 patients) or best supportive care alone (285 patients). The primary end point was overall survival. RESULTS: In comparison with best supportive care alone, cetuximab treatment was associated with a significant improvement in overall survival (hazard ratio for death, 0.77; 95% confidence interval [CI], 0.64 to 0.92; P=0.005) and in progression-free survival (hazard ratio for disease progression or death, 0.68; 95% CI, 0.57 to 0.80; P<0.001). These benefits were robust after adjustment in a multivariable Cox proportional-hazards model. The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group assigned to supportive care alone. Partial responses occurred in 23 patients (8.0%) in the cetuximab group but in none in the group assigned to supportive care alone (P<0.001); the disease was stable in an additional 31.4% of patients assigned to cetuximab and in 10.9% of patients assigned to supportive care alone (P<0.001). Quality of life was better preserved in the cetuximab group, with less deterioration in physical function and global health status scores (both P<0.05). Cetuximab treatment was associated with a characteristic rash; a rash of grade 2 or higher was strongly associated with improved survival (hazard ratio for death, 0.33; 95% CI, 0.22 to 0.50; P<0.001). The incidence of any adverse event of grade 3 or higher was 78.5% in the cetuximab group and 59.1% in the group assigned to supportive care alone (P<0.001). CONCLUSIONS: Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed. (ClinicalTrials.gov number, NCT00079066 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cetuximab is a chimeric (mouse/human) monoclonal IgG1 antibody developed to bind the extracellular EGFR domain that blocks dimerization and ligand-induced signaling of the EGFR pathway [14].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
In the citing paper
“Patients who received cetuximab had a 6.1-month median survival compared with 4.6 months among individuals in the best supportive care group.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Research works printed but not linked: 3
- Mellstedt H, 2003, Drugs Today (Barc), 39, 1
- Eng C, 2007, J Clin Oncol, 25, 18s
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
Cited by
Items 701–800 of 1,001
Research progress in targeted therapy and immunotherapy for gastric cancer
Li, X., Xu, J., Xie, J., & Yang, W. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002185 · Cited by 27
“[4-11] The treatment and diagnosis of GC have made great progress with the in-depth study of the gene sequence and”
BackgroundChemotherapy for Penile and Urethral Carcinoma
Trabulsi, E. J., & Hoffman-Censits, J. H. (2010) · Urologic Clinics of North America · doi:10.1016/j.ucl.2010.04.010 · Cited by 27
Rash Rates with EGFR Inhibitors: Meta-Analysis
Mittmann, N., & Seung, S. J. (2011) · Current Oncology · doi:10.3747/co.v18i2.605 · Cited by 28
“%) because of cetuximab- related infusion reactions (B) Gemcitabine plus platinum 66 Gr 3/4: (A) n=8, 14.1%; (B) n=0 (131) Jonker et al., 2007 9 Metastatic colorectal cancer Randomized controlled trial for 20 months until progression or death (A) Cetuximab plus bsc vs. 287 Gr 3 or higher: (A)…”
BackgroundInfluentialAntibody-Based Immunotherapy of Solid Cancers: Progress and Possibilities
Nicodemus, C. F. (2015) · Immunotherapy · doi:10.2217/imt.15.57 · Cited by 28
Bertino, E. M., McMichael, E. L., Mo, X. M., Trikha, P., Davis, M. E., Paul, B. K., Grever, M. R., Carson, W. E., & Otterson, G. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0879 · Cited by 32
Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer
Gill, S., Berry, S. R., Biagi, J., Butts, C., Buyse, M. E., Chen, E., Jonker, D., Marginean, C. E., Samson, B., Stewart, J., et al. (2011) · Current Oncology · doi:10.3747/co.v18is2.941 · Cited by 34
Self-citationSignaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer
Mirone, G., Shukla, A. K., & Marfè, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.012 · Cited by 32
Han, S., Oh, D., Im, S., Park, S. R., Lee, K., SONG, H. S., Lee, N., Lee, K. H., Choi, I. S., Lee, M. H., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01447.x · Cited by 26
Gallagher, D. J., Al‐Ahmadie, H. A., Ostrovnaya, I., Gerst, S. R., Regazzi, A. M., Garcia-Grossman, I. R., Riches, J. C., Gounder, S., Flaherty, A.-M., Trout, A., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.05.034 · Cited by 26
Negri, F., Musolino, A., Naldi, N., Bortesi, B., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Chernyschova, N., Bisagni, G., et al. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2012.54 · Cited by 29
Song, X., Long, S. R., Barber, B., Kassed, C. A., Healey, M., Jones, C., & Zhao, Z. (2012) · Current Clinical Pharmacology · doi:10.2174/157488412799218806 · Cited by 28
The safety of monoclonal antibodies for treatment of colorectal cancer
Berger, M. D., & Lenz, H. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1167186 · Cited by 27
Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
Martins, M., Mansinho, A., Cruz-Duarte, R., Lobo-Martins, S., & Costa, L. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_8 · Cited by 30
Soda, H., Maeda, H., Hasegawa, J., Takahashi, T., Hazama, S., Fukunaga, M., Kono, E., Kotaka, M., Sakamoto, J., Nagata, N., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1685-z · Cited by 28
Bouché, O., Beretta, G. D., Alfonso, P., & Geißler, M. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)00036-8 · Cited by 36
Christoffersen, T., Guren, T. K., Spindler, K. G., Dahl, O., Lønning, P. E., & Gjertsen, B. T. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.009 · Cited by 29
Ibrahim, E. M., Zekri, J., & Sadiq, B. M. B. (2010) · International Journal of Colorectal Disease · doi:10.1007/s00384-010-0927-4 · Cited by 28
“Nevertheless, in this meta-analysis only two large studies were included [30, 31], and in one of them, the OS advantage was not demonstrated [31].”
BackgroundThe Expanding Role of Therapeutic Antibodies
Salemi, S., Marković, M., Martini, G., & D’Amelio, R. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2013.863304 · Cited by 27
Jin, D.-J., Fang, Y., Li, Z., Chen, Z., & Xiang, J. (2014) · Oncology Reports · doi:10.3892/or.2014.3638 · Cited by 31
Serum and tissue markers in colorectal cancer: State of art
Berretta, M., Alessandrini, L., Divitiis, C. D., Nasti, G., Lleshi, A., Francia, R. D., Facchini, G., Cavaliere, C., Buonerba, C., & Canzonieri, V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.007 · Cited by 29
Novel biotechnology approaches in colorectal cancer diagnosis and therapy
Kavousipour, S., Khademi, F., Zamani, M., Vakili, B., & Mokarram, P. (2017) · Biotechnology Letters · doi:10.1007/s10529-017-2303-8 · Cited by 26
Valverde, A. M., Peñarando, J., Cañas, A., Lopez-Sanchez, L. M., Conde, F., Guil‐Luna, S., Hernandez, V. A., Villar, C., Morales-Estévez, C., de la Haba-Rodríguez, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15567 · Cited by 26
Targeting Receptor Tyrosine Kinases in Cancer
Köstler, W. J., & Zielinski, C. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_10 · Cited by 40
KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas
Alexander, R. E., López-Beltrán, A., Montironi, R., MacLennan, G. T., Post, K. M., Bilbo, S. A., Jones, T. D., Huang, W., Rao, Q., Sen, J. D., et al. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04309.x · Cited by 30
The Challenge of Metastatic Colorectal Cancer
Cidón, E. U. (2010) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s5214 · Cited by 29
Kang, M. J., Hong, Y. S., Kim, K., Kim, S. Y., Baek, J. Y., Ryu, M., Lee, J., Chang, H. M., Kim, M., Chang, H. J., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9703-8 · Cited by 27
“The standard protocol for cetuximab treatment is weekly administration [ 7 , 17].”
BackgroundResultMolecularly-targeted therapy for the oral cancer stem cells
Ohnishi, Y., Yasui, H., Nozaki, M., & Nakajima, M. (2017) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2017.11.001 · Cited by 28
Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma
Chia, P. L., Scott, A. M., & John, T. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1598374 · Cited by 28
Blank‐Landeshammer, B., Richard, V. R., Mitsa, G., Marques, M., LeBlanc, A. M., Kollipara, L., Feldmann, I., du Tertre, M. C., Gambaro, K., McNamara, S., et al. (2019) · Cancers · doi:10.3390/cancers11121907 · Cited by 26
“An important determinant of whether patients are eligible for anti-EGFR therapies is their KRAS mutational status, which has become a validated predictor of non-response to anti-EGFR antibodies [8].”
BackgroundVáradi, C., Jakes, C., & Bones, J. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.113035 · Cited by 25
Epitope Mapping of an Antihuman EGFR Monoclonal Antibody (EMab-134) Using the REMAP Method
Sano, M., Kaneko, M. K., Asano, T., & Kato, Y. (2021) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2021.0014 · Cited by 26
Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma
Chen, K., Si, Y., Guan, J.-S., Zhou, Z. “., Kim, S., Kim, T. H., Shan, L., Willey, C. D., Zhou, L., & Liu, M. (2022) · Biomedicines · doi:10.3390/biomedicines10010130 · Cited by 25
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
McFall, T. B., Trogdon, M., Guizar, A. C., Langenheim, J. F., Sisk-Hackworth, L., & Stites, E. C. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00329-w · Cited by 29
Lee, C., Lee, M. E., Lee, W. S., Kim, J., Park, K.-H., Kim, T. S., Lee, K. Y., Ahn, J. B., Chung, H. C., & Rha, S. Y. (2015) · Europe PMC (PubMed Central) · Cited by 29
Monoclonal antibodies therapies for ovarian cancer
Maggiore, U. L. R., Bellati, F., Ruscito, I., Gasparri, M. L., Alessandri, F., Venturini, P. L., & Ferrero, S. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.767328 · Cited by 26
Mancl, E. E., Kolesar, J., & Vermeulen, L. C. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090036 · Cited by 29
Adjuvant Therapy for Early Colon Cancer: Current Status
Stein, A., Hiemer, S., & Schmoll, H. (2011) · Drugs · doi:10.2165/11594490-000000000-00000 · Cited by 25
Arnold, D., & Stein, A. (2013) · Drugs · doi:10.1007/s40265-013-0076-5 · Cited by 25
Patel, S. P., Bristol, A., Saric, O., Wang, X.-P., Dubeykovskiy, A., Arlen, P. M., & Morse, M. A. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1420-z · Cited by 25
New targeted therapies for gastric cancer
Asaoka, Y., Ikenoue, T., & Koike, K. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.566863 · Cited by 25
Pietrantonio, F., Maggi, C., Bartolomeo, M. D., Facciorusso, M. G., Perrone, F., Testi, M., Iacovelli, R., Miceli, R., Bossi, I. E., Leone, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092147 · Cited by 26
Qi, W., Fu, S., Zhang, Q. H., & Guo, X. (2014) · BMC Medicine · doi:10.1186/preaccept-1633779014133168 · Cited by 25
Multidisciplinary Management of Locally Advanced Rectal Cancer—An Evolving Landscape?
Lee, M., Gibbs, P., & Wong, R. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.06.002 · Cited by 26
Nishiofuku, H., Tanaka, T., Aramaki, T., Boku, N., Inaba, Y., Sato, Y., Matsuoka, M., Otsuji, T., Arai, Y., & Kichikawa, K. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.044 · Cited by 25
Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer
Balakrishnan, A., Vyas, A. K., Deshpande, K. S., & Vyas, D. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2159 · Cited by 26
Pinto, C., Fabio, F. D., Rosati, G., Lolli, I. R., Ruggeri, E. M., Ciuffreda, L., Ferrari, D., Re, G. L., Rosti, G., Tralongo, P., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.888 · Cited by 25
Neuzillet, C., Rousseau, B., Kocher, H. M., Bourget, P., & Tournigand, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.028 · Cited by 26
Saida, K., Murase, T., Ito, M., Fujii, K., Takino, H., Masaki, A., Kawakita, D., Ijichi, K., Tada, Y., Kusafuka, K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24818 · Cited by 26
Peritoneal Metastases in Colorectal Cancer
Jacobson, R. A., Sherman, S. K., Dadaleh, F., & Turaga, K. K. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6490-x · Cited by 25
Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of Cancer
de Torres, C. S., Baraibar, I., Gonzalez, N. S., Ros, J., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136967 · Cited by 29
“Anti-EGFR antibodies (cetuximab and panitumumab) have improved outcomes in patients with RAS wild-type advanced CRC [9,10], whereas activating mutations in KRAS or NRAS , present in 52% of metastatic CRC [11], provide resistance to anti-EGFR therapies, as the downstream activation of the signaling…”
BackgroundCancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: anin vivostudy
Asadi‐Ghalehni, M., Ghaemmaghami, M., Klimka, A., Javanmardi, M., Navari, M., & Rasaee, M. J. (2015) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1027917 · Cited by 24
Integrating anti-EGFR therapies in metastatic colorectal cancer.
Haraldsdóttir, S., & Bekaii‐Saab, T. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.028 · Cited by 28
Giampieri, R., Scartozzi, M., Prete, M. D., Maccaroni, E., Bittoni, A., Faloppi, L., Bianconi, M., Cecchini, L., & Cascinu, S. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.008 · Cited by 25
“[3] Jonker DJ, O’Callaghan CJ, Karapetis CS, et al.”
BackgroundMethodCabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer
Strickler, J. H., Rushing, C. N., Uronis, H. E., Morse, M. A., Niedzwiecki, D., Blobe, G. C., Moyer, A. N., Bolch, E. K., Webb, R., Haley, S. T., et al. (2021) · The Oncologist · doi:10.1002/onco.13678 · Cited by 26
Local γδ T cells: translating promise to practice in cancer immunotherapy
Zlatareva, I., & Wu, Y. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02303-0 · Cited by 27
Treatment of metastatic colorectal cancer: focus on panitumumab
Hawkes, E. A., Tay, R. Y., & Wong, R. (2015) · Cancer Management and Research · doi:10.2147/cmar.s71821 · Cited by 29
KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice
Fakih, M. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.003 · Cited by 26
Gao, J., Li, Y.-Y., Sun, P.-N., & Shen, L. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i38.4858 · Cited by 26
SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013
Sáenz, E. C., Feliú, J., Gómez‐España, M. A., Sánchez-Gastaldo, A., & García‐Carbonero, R. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1082-5 · Cited by 27
Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept
Ocaña, A., Amir, E., Vera-Badillo, F., Šeruga, B., & Tannock, I. F. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1222 · Cited by 24
REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY
Lynch, J. P., Metz, D. C., Schuppan, D., Junker, Y., & Barisani, D. (2009) · Cited by 24
Bonin, S., Donada, M., Bussolati, G., Nardon, E., Annaratone, L., Pichler, M., Chiaravalli, A. M., Capella, C., Höefler, G., & Stanta, G. (2015) · Tumor Biology · doi:10.1007/s13277-015-4543-3 · Cited by 24
Faugeras, L., Dili, A., Druez, A., Krug, B., Decoster, C., & D'Hondt, L. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.029 · Cited by 28
“It can also be administered as monotherapy in patients ho were treated previously with fluoropyrimidines, irinotecan, nd oxaliplatin (Jonker et al., 2007).”
BackgroundUozumi, S., Enokida, T., Suzuki, S., Nishizawa, A., Kamata, H., Okano, T., Fujisawa, T., Ueda, Y., Okano, S., Tahara, M., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00616 · Cited by 24
“Nasopharynx 15 (13) Oropharynx 12 (11) Larynx 13 (12) Treatment regimen, n (%) 5-FU + CDDP or CBDCA + Cmab 33 (30) PTX + CBDCA + Cmab 36 (32) PTX + Cmab 43 (38)”
BackgroundInfluentialCurrent Development of Monoclonal Antibodies in Cancer Therapy
Parakh, S., King, D., Gan, H. K., & Scott, A. M. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_1 · Cited by 28
Delord, J., Argilés, G., Fayette, J., Wirth, L. J., Kasper, S., Siena, S., Mesía, R., Berardi, R., Cervantes, A. M. R., Dekervel, J., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00928-z · Cited by 25
Liu, L., Cao, Y., Tan, A., Liao, C., & Gao, F. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1090-x · Cited by 26
“According to the result of sensitivity analysis, two trials [23, 24] were excluded.”
BackgroundResultInfluentialGene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2
Kim, S., Danishmalik, S. N., Hwang, H., Sin, J.-I., Oh, J., Cho, Y., Lee, H., Jeong, M., Kim, S.-H., & Hong, H. J. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.37 · Cited by 24
Cho, S.-Y., Han, J. Y., Na, D., Kang, W., Lee, A., Kim, J., Lee, J., Min, S., Kang, J., Chae, J., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0735 · Cited by 24
Sakai, D., Taniguchi, H., Sugimoto, N., Tamura, T., Nishina, T., Hara, H., Esaki, T., Denda, T., Sakamoto, T., Okuda, H., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.04.014 · Cited by 23
Baba, Y., Tamura, T., Satoh, Y., Gotou, M., Sawada, H., Ebara, S., Shibuya, K., Soeda, J., & Nakamura, K. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12074 · Cited by 23
Wainberg, Z. A., & Drakaki, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1050375 · Cited by 25
Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned
Towse, A., Ossa, D., Veenstra, D. L., Carlson, J. J., & Garrison, L. P. (2013) · Journal of Personalized Medicine · doi:10.3390/jpm3040288 · Cited by 23
Jankú, F., Berry, D. A., Gong, J., Parsons, H. A., Stewart, D. J., & Kurzrock, R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0178 · Cited by 25
Chibaudel, B., Bonnetain, F., Tournigand, C., de Larauze, M. H., Gramont, A. D. E., Laurent‐Puig, P., Paget, J., Hadengue, A., Notelet, D., Benetkiewicz, M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1503-7 · Cited by 25
Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer
Lee, S., & Oh, S. C. (2016) · BioMed Research International · doi:10.1155/2016/7590245 · Cited by 25
Pilbeam, K., Wang, H., Taras, E. P., Bergerson, R. J., Ettestad, B., DeFor, T. E., Borgatti, A., Vallera, D. A., & Verneris, M. R. (2017) · Oncotarget · doi:10.18632/oncotarget.21187 · Cited by 23
Hoch, J. S., Hay, A. E., Isaranuwatchai, W., Thavorn, K., Leighl, N. B., Tu, D., Trenaman, L., Dewa, C. S., O’Callaghan, C. J., Pater, J. L., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5779-x · Cited by 23
Self-citationTsuji, A., Nakamura, M., Watanabe, T., Manaka, D., Matsuoka, H., Kataoka, M., Takeuchi, M., Ichikawa, W., & Fujii, M. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00845-y · Cited by 25
Jenkins, L. J., Luk, I. Y., Fairlie, W. D., Lee, E. F., Palmieri, M., Schoffer, K. L., Tan, T., Ng, I., Vukelic, N., Tran, S. H., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0101 · Cited by 25
Self-citationTabata, S., Goi, T., NAKAZAWA, T., Kimura, Y., Katayama, K., & YAMAGUCHI, K. (2012) · Oncology Reports · doi:10.3892/or.2012.2124 · Cited by 25
The impact of genomics on public health practice
Burton, H., Jackson, C., & Abubakar, I. I. (2014) · British Medical Bulletin · doi:10.1093/bmb/ldu032 · Cited by 24
Douillard, J., Zemełka, T., Fountzilas, G., Barone, C. A., Schlichting, M., Heighway, J., Eggleton, S. P., & Srimuninnimit, V. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.11.009 · Cited by 26
Belum, V. R., Cercek, A., Sanz‐Motilva, V., & Lacouture, M. E. (2013) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0254-4 · Cited by 24
Sequencing of treatment in metastatic colorectal cancer: Where to fit the target
Temraz, S. N., Mukherji, D., & Shamseddine, A. I. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i8.1993 · Cited by 27
Clinical Update: Colon, Rectal, and Anal Cancers
Wilkes, G. M., & Hartshorn, K. L. (2012) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2012.09.012 · Cited by 28
Argiris, A., Feinstein, T. M., Wang, L., Yang, T., Agrawal, S., Appleman, L. J., Stoller, R. G., Grandis, J. R., & Egloff, A. M. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9732-3 · Cited by 23
Verweij, J., de Jonge, M. J. A., Eskens, F. A. L. M., & Sleijfer, S. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.009 · Cited by 23
“…practice, but also for cytotoxic treatment these aims seem to hold in diseases as colorectal carcinoma, nonsmall cell lung cancer and (albeit maybe less convincing) breast cancer (Koopman et al., 2007; Marsland et al., 2005; Felip et al., 1998; Carrick et al., 2009; de Bono and Ashworth, 2010).”
BackgroundOhnishi, Y., Minamino, Y., Kakudo, K., & Nozaki, M. (2014) · Oncology Reports · doi:10.3892/or.2014.3258 · Cited by 24
Zhang, X., Shimodaira, H., Soeda, H., Komine, K., Takahashi, H., Ouchi, K., Inoue, M., Takahashi, M., Takahashi, S. I., & Ishioka, C. (2016) · International Journal of Clinical Oncology · doi:10.1007/s10147-016-1017-6 · Cited by 23
Biomarker-driven and molecular targeted therapies for colorectal cancers
Schirripa, M., Cohen, S. A., Battaglin, F., & Lenz, H. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.003 · Cited by 27
“Cetuximab and panitumumab, two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, have been approved by the US Food and Drug Administration (FDA) >10 years ago for the treatment of mCRC, based on the results of randomized trials proving their efficacy in advanced lines of treatment [7,8].”
BackgroundMolecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies
Chang, S. T., Menias, C. O., Lubner, M. G., Mellnick, V. M., Hara, A. K., & Desser, T. S. (2017) · Radiographics · doi:10.1148/rg.2017160162 · Cited by 23
Shepshelovich, D., Townsend, A. R., Espin‐Garcia, O., Latifovic, L., O’Callaghan, C. J., Jonker, D. J., Tu, D., Chen, E. X., Morgen, E. K., Price, T. J., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1819 · Cited by 23
Self-citationKim, S., Pak, K., & Kim, K. (2019) · Abdominal Radiology · doi:10.1007/s00261-018-01891-3 · Cited by 27
Jugler, C., Joensuu, J. J., & Chen, Q. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062140 · Cited by 23
“Examples of mAb-therapeutics include cetuximab to treat colorectal cancer [2], avelumab to treat a variety of tumors [3], and the combination of three anti-Ebola mAbs, known as ZMapp, to treat Ebola virus infection [4].”
BackgroundKurai, J., Chikumi, H., Hashimoto, K., Takata, M., Sako, T., YAMAGUCHI, K., Kinoshita, N., Watanabe, M., Touge, H., Makino, H., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1607 · Cited by 29
Alkan, A., Hofving, T., Angenete, E., & Yrlid, U. (2021) · Biomarker Research · doi:10.1186/s40364-021-00313-9 · Cited by 25
Quality of life in patients with K‐RAS wild‐type colorectal cancer
Ringash, J. G., Au, H., Siu, L. L., Shapiro, J. D., Jonker, D. J., Zalcberg, J. R., Moore, M. J., Strickland, A. H., Kotb, R. R., Jeffery, M., et al. (2013) · Cancer · doi:10.1002/cncr.28410 · Cited by 22
Self-citationMutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients
Rako, I., JAKIC-RAZUMOVIC, J., Katalinić, D., Sertić, J., & Pleština, S. (2012) · Neoplasma · doi:10.4149/neo_2012_049 · Cited by 23
Beyond KRAS Status and Response to Anti-EGFR Therapy in Metastatic Colorectal Cancer
Perkins, G., Pilati, C., Blons, H., & Laurent-Puig, P. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.66 · Cited by 22
Metadata
- Authors
- Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., Tebbutt, N. C., van Hazel, G., Wierzbicki, R., Langer, C., & Moore, M. J.
- Affiliations
- University of Ottawa (CA)
- Flinders Medical Centre (AU)
- The University of Melbourne (AU)
- Queen's University (CA)
- Cross Cancer Institute (CA)
- Sunnybrook Health Science Centre (CA)
- St. Boniface Hospital (CA)
- Queen Elizabeth Hospital (AU)
- The University of Sydney (AU)
- Austin Health (AU)
- Lakeridge Health (CA)
- Bristol-Myers Squibb (United States) (US)
- Princess Margaret Cancer Centre (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2040-2048
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115790682
- Cited by
- 1,904
- References
- 20
- Citations by year
- 2026: 23 · 2025: 47 · 2024: 56 · 2023: 60 · 2022: 62 · 2021: 63 · 2020: 87 · 2019: 82 · 2018: 84 · 2017: 101 · 2016: 110 · 2015: 133 · 2014: 143 · 2013: 150 · 2012: 153
- FWCI
- 68.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- cetuximab, colorectal cancer, epidermal growth factor receptor, EGFR-positive tumors, monoclonal antibody therapy, best supportive care, overall survival, progression-free survival, rash, quality of life, adverse events, irinotecan, oxaliplatin, fluoropyrimidine
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Exanthema, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Colorectal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.